143 results
Page 7 of 8
DRS
uzy2kh
18 Dec 20
Draft registration statement
12:00am
6-K
EX-99.1
2beq22sl ayg6l
17 Dec 20
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
6:15am
6-K
nd6ixrkj2j8ahvns4
9 Dec 20
Current report (foreign)
4:23pm
6-K
EX-99.1
udsftzh7cawyhigtr
9 Dec 20
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
6:30am
6-K
EX-99.1
ky18h
8 Dec 20
Amryt Announces $40m Private Placement with Leading Biotech Investors
6:05am
6-K
EX-99.1
pna 1kzjtpq9w5
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
EX-99.1
5fe6xzg6 l33oq
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
6-K
EX-99.1
wrc9 qes2o899zkolblv
19 Oct 20
Current report (foreign)
8:00am
6-K
EX-99.1
atanhftglopj01d b64
15 Sep 20
Current report (foreign)
8:31am
6-K
EX-99.1
n7o02q2k46u9rzd
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
EX-99.1
75k80mut
11 Aug 20
Notification of Cancellation of Admission to Euronext Growth
10:04am
6-K
EX-99.1
mnohmhur8bk036f246x
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
6-K
EX-99.1
rch bmg9bkixvawk7y1d
10 Jul 20
Current report (foreign)
9:46am
424B4
hbn06q6yg49qif5oq
8 Jul 20
Prospectus supplement with pricing info
4:05pm
F-1/A
iqn4ubum
6 Jul 20
Registration statement (foreign) (amended)
5:28pm
F-1
EX-10.2
qftph9mmkbblbpwh
23 Jun 20
Registration statement (foreign)
5:21pm
F-1
EX-10.5
6llvw6xri
23 Jun 20
Registration statement (foreign)
5:21pm
F-1
akchfa9g70y9
23 Jun 20
Registration statement (foreign)
5:21pm
F-1
EX-2.1
ny0r0p yo
23 Jun 20
Registration statement (foreign)
5:21pm
DRS/A
0om0npoot7xjey
29 May 20
Draft registration statement (amended)
12:00am